High-contrast in-vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies

Kenji Tagai[1,2†], Maiko Ono[1†], Manabu Kubota[1,3†], Soichiro Kitamura[1,4], Keisuke Takahata[1,5], Chie Seki[1], Yuhei Takado[1], Hitoshi Shinotoh[1,6], Yasunori Sano[1,5], Kiwamu Matsuoka[1,4], Hiroyuki Takuwa[1], Masafumi Shimojo[1], Manami Takahashi[1], Kazunori Kawamura[1], Tatsuya Kikuchi[1], Maki Okada[1], Haruhiko Akiyama[7], Hisaomi Suzuki[1,5,8], Mitsumoto Onaya[8], Takahiro Takeda[9], Kimihito Arai[9], Nobutaka Arai[10], Nobuyuki Araki[9], Yuko Saito[11], Yasuyuki Kimura[1,12], Masanori Ichise[1], Yutaka Tomita[13], Ming-Rong Zhang[1], Tetsuya Suhara[1,2], Masahiro Shigeta[2], Naruhiko Sahara[1], Makoto Higuchi[1*], Hitoshi Shimada[1]

[1]National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan

[2]Department of Psychiatry, The Jikei University Graduate School of Medicine, Tokyo 105-8461, Japan

[3]Department of Psychiatry, Kyoto University Graduate School of Medicine 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

[4]Department of Psychiatry, Nara Medical University, Nara 634-8521, Japan

[5]Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan

[6]Neurology Clinic Chiba, Chiba 263-8555, Japan

[7]Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan

[8]National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba 266-0007, Japan

[9]Department of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba 260-8712, Japan

[10]Laboratory of Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan

[11]National Center of Neurology and Pathology Brain Bank, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan

[12]Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan

[13]Tomita Hospital, Aichi 444-3505, Japan

†These authors contributed equally to this work.

*Corresponding author: Makoto Higuchi, M.D., Ph.D.

National Institute of Radiological Sciences, National Institutes for Quantum and

Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan

Phone +81-43-206-4700, Fax +81-43-253-0396

Email higuchi.makoto@qst.go.jp

One Sentence Summary: We developed a positron emission tomography probe for tau

fibrils in an animal model and patients with Alzheimer's disease and non-Alzheimer's

disease tauopathies with high contrast, enabling translational assessments of the tau

pathogenesis and diagnostic evaluations of disease-specific and stage-dependent tau

topologies on an individual basis.

Abstract

Depositions of fibrillary tau protein aggregates are implicated in diverse tauopathies,

including Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). A

panel of radiochemicals has enabled *in-vivo* positron emission tomography (PET) of AD

tau pathologies composed of all six tau isoforms, while sensitive detection of FTLD tau

inclusions, mostly consisting of tau isoforms with three or four repeat domains only, has

been unsuccessful. Here, we generated an imaging probe, PM-PBB3, for capturing tau

deposits with all isoform composites. *In-vitro* assays demonstrated the reactivity of this

compound with tau pathologies in AD, four-repeat tauopathies such as progressive

supranuclear palsy (PSP) and corticobasal degeneration (CBD), and three-repeat

tauopathies represented by Pick's disease (PiD). We could also utilize PM-PBB3 for

bimodal, multiscale optical/PET imaging of a living murine tauopathy model. A

subsequent clinical PET study revealed increased binding of radiolabeled ^{18}F-PM-PBB3

in diseased patients, reflecting cortical-dominant AD and subcortical-dominant PSP tau

topologies. Notably, the *in-vivo* reactivity of ^{18}F-PM-PBB3 with three- and four-repeat

tau lesions was strongly supported by neuropathological examinations of autopsied and

biopsied brains derived from PiD, PSP and CBD patients who underwent PET scans.

Finally, visual inspection of ^{18}F-PM-PBB3-PET images was indicated to facilitate

individually based identification of the neuropathological basis, composed of PSP, CBD

and PiD, underlying the diverse clinical phenotypes of FTLD. Taking these findings

together, we propose the new tau probe as a powerful tool for etiological, diagnostic and

therapeutic PET assessments of the tau pathogenesis in AD and FTLD spectra at

nonclinical and clinical levels.

(248 words)

INTRODUCTION

The vast majority of age-related neurodegenerative diseases are characterized as

protein conformational disorders, involving self-assemblies of misfolded proteins into

fibrillary aggregates (*1, 2*). Among these pathogenic proteins, the fibrillogenesis of

microtubule-associated protein tau occurs as a hallmark pathological change in diverse

illnesses referred to as tauopathies, and it is mechanistically linked to the

neurodegenerative processes in these disorders (*3, 4*). Tau in the central nervous system

is composed of six isoforms, which are classified into three- and four-repeat species

according to the number of repeat domains (*5*). Alzheimer's disease (AD) and AD-type

primary age-related tauopathy (PART) are characterized by tau pathologies formed by all

isoforms, while a significant subset of frontotemporal lobar degeneration (FTLD)

syndromes is neuropathologically unfolded by exclusive fibrillization of either three- or

four-repeat tau isoforms (*5, 6*). The differences in the isoform composition among these

tauopathies lead to diversities in the conformation and ultrastructures of tau fibrils as

revealed by recent cryo-electron microscopic assays (*7, 8*).

The distinct tau conformers are likely to determine subcellular, cellular, and regional

localization of tau deposits in a disease-specific fashion, provoking characteristic

symptoms associated with deteriorations of affected neurons and neural circuits (*9*). In

line with this mechanism, there exist clear distinctions among neuropathological features

of AD/PART and major tau-positive FTLD disorders, including three-repeat tauopathies

represented by Pick's disease (PiD) and four-repeat tauopathies exemplified by

progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) (*6*).

Meanwhile, substantial overlaps have been noted among symptomatic phenotypes

derived from these pathologies, impeding the differentiation of clinical syndromes by

estimation of underlying pathological alterations (*10-12*).

In-vivo imaging technologies such as positron emission tomography (PET) with

specific radioligands for amyloid-beta and tau fibrils have enabled visualization of AD-

type neuropathologies in living subjects, facilitating diagnosis and staging of AD

dementia and its prodrome. The tau PET probes available for these clinical assays are

classified into three chemotypes consisting of ^{18}F-labeled THK5351 (*13*), ^{18}F-labeled

flortaucipir (*14*), and ^{11}C-labeled PBB3 (*15, 16*) series originating from nonclinical

prototypes BF-158/BF-170 (*17*), BF-126 (*17*), and styryl 7 (PBB5) (*15*), respectively.

Unlike for AD tau lesions, high-contrast PET detection of three- and four-repeat tau

deposits in FTLD patients has been unsuccessful, as tau-related radiosignals yielded by ^{18}F-flortaucipir and ^{11}C-PBB3 in PSP and CBD cases were less than 20% of the corresponding signals in patients with advanced AD (*18, 19*). ^{18}F-THK5351 was reported to illuminate brain areas putatively enriched with PSP and CBD tau inclusions (*20, 21*), but those observations were attributed to the cross-reactivity of this compound with monoamine oxidase B (MAO-B), which is upregulated in reactive astrocytes (*22, 23*). In addition, most 'second-generation' tau PET probes are analogs of ^{18}F-fluotaucipir and are not overtly more reactive with non-AD tau assemblies than ^{18}F-fluotaucipir and ^{11}C-PBB3 (*24-26*).

   ^{11}C-PBB3 was originally designed to capture tau fibrils in a wide range of tauopathies (*15*) and was demonstrated to react with three- and four-repeat tau aggregates in human brain tissues with a higher binding potential than ^{18}F-flortaucipir (*27*). However, rapid conversion of ^{11}C-PBB3 into a metabolite resulted in a relatively low entry of the unmetabolized compound into the brain (*15, 28, 29*), hampering a sensitive recognition of fibrillary aggregates in FTLD tauopathies that are less abundant than AD tau deposits. To overcome this technical issue, in the current work we modified the chemical structure of PBB3 to generate a chemical with a relatively high metabolic stability, aiming at unambiguous investigations of tau fibril density and extent in each of the individuals with AD and FTLD. The new compound, PM-PBB3 (propanol modification of PBB3), was also fluorinated in consideration of advantages of an ^{18}F-labeled probe over ^{11}C-radiochemicals for broader availability and higher PET scan throughput. Nonclinical assays revealed the capability of PM-PBB3 for high-sensitivity illumination of tau pathologies in a murine model bimodally by *in-vivo* optical and PET imaging from single-cell to brain-wide scales, potentially serving for the discovery of candidate therapeutics counteracting the neurodegenerative tau pathogenesis. Subsequent applications of ^{18}F-PM-PBB3 to clinical PET assays, along with neuropathological data obtained from scanned subjects, demonstrated appropriate kinetic and binding profiles of this probe for personalized evaluations of tau depositions in AD and various FTLD syndromes.

RESULTS

***In-vitro* binding of PM-PBB3 to AD- and FTLD-type tau aggregates**

   The original compound, PBB3 (Fig. 1a), was found to be promptly conjugated with sulfate at a hydroxy moiety following systemic injection (*28*). To suppress this metabolic conversion, we substituted this substructure with the fluoro-isopropanol group, resulting in the generation of PM-PBB3 (Fig. 1a). This modification also allowed ^{18}F radiolabeling

of the probe using a tosylate precursor (Figure S1). Similar to PBB3 (*15, 27*), PM-PBB3

is self-fluorescent, and its reactivity with pathological tau fibrils is assessable by

fluorescence labeling of brain sections derived from tauopathy patients. Triple staining of

brain slices with PM-PBB3, antibody against phosphorylated tau (AT8), and Gallyas-

Braak silver impregnation (GB) demonstrated binding of PM-PBB3 to neurofibrillary

tangles (NFT), neuropil threads, and dystrophic neurites encompassing neuritic plaques

in AD hippocampal formation, which were composed of six tau isoforms (Fig. 1b).

Furthermore, PM-PBB3 conspicuously illuminated Pick bodies constituted of three-

repeat tau isoforms in PiD frontal cortex and four-repeat tau lesions such as tufted

astrocytes in PSP striatum, astrocytic plaques in CBD striatum, and coiled bodies and

argyrophilic grains and threads in these tissues (Fig. 1b).

We then radiosynthesized ^{18}F-PM-PBB3 and examined its *in-vitro* binding

characteristics. Autoradiography of tissue sections demonstrated that ^{18}F-PM-PBB3

radiosignals were intensely distributed in the anatomical structures enriched with AD and

PSP tau fibrils, as exemplified by gray matter of the hippocampal formation and inferior

temporal cortex in the AD brain and gray and white matter of the motor cortex in the PSP

brain (Fig. 1c). Radioligand binding was profoundly abolished by excessive non-

radioactive PBB5 (Fig. 1c). Localization of the autoradiographic labeling was in line with

histological features obtained from the same sections, as abundant NFTs and neuropil

threads in the AD subiculum (area 1), and coiled bodies and tufted astrocytes in middle

gray matter layers of the PSP motor cortex (area 3) were captured by non-radiolabeled

PM-PBB3 (areas 1, 3 in Figure 1d). In contrast, the lack of overt autoradiographic

radioligand binding spatially agreed with minimal PM-PBB3 fluorescence in white matter

of the AD temporal cortex, and in superficial gray matter layers of the PSP motor cortex

(areas 2, 4 in Fig. 1d).

We also quantified the affinity of ^{18}F-PM-PBB3 for tau aggregates in homogenized AD

frontal cortical and PSP motor cortical tissues. Radioligand binding in these tissues was

homologously blocked by non-radiolabeled PM-PBB3 in a concentration-dependent

fashion (Fig. 1e), indicating binding saturability. ^{18}F-PM-PBB3 displayed high-affinity,

high-capacity binding in AD homogenates [dissociation constant (K_D), 7.63 nM;

concentration of binding components (B_{max}), 5743 pmol/g; binding potential (BP = B_{max}

/ K_D), 752.7] (Fig. 1f). The radioligand bound in PSP tissues with lower capacity but

higher affinity than in AD tissues (K_D, 3.44 nM; B_{max}, 688.2 pmol/g; BP, 199.9). The BP

for [18F]PM-PBB3 in PSP homogenates was 1.6 times higher than the value for

[11C]PBB3 in the same samples (*27*). The binding of ^{18}F-PM-PBB3 in AD homogenates

was partially and heterologously blocked by BTA-1, which is a Pittsburgh Compound-B

(PiB) analog and binds to Aβ aggregates with high affinity, with a large inhibition constant (Ki) value (379.1 nM) (Fig. 1g), suggesting that ^{18}F-PM-PBB3 is incapable of sensitively capturing Aβ deposits in AD homogenates (*30, 31*). Moreover, the heterologous blockade by BTA-1 is likely to stem primarily from its low-affinity binding to AD tau fibrils. Notably, minimal displacement of ^{18}F-PM-PBB3 binding was observed in the presence of the monoamine oxidase A (MAO-A) inhibitor clorgiline, or the (MAO-B) inhibitor selegiline, in AD frontal cortex homogenates (Fig. 1g), suggesting that ^{18}F-PM-PBB3 barely cross-reacts with off-target binding sites on monoamine oxidases, unlike the reported binding of ^{18}F-THK5351 and ^{18}F-flortaucipir to MAO-B (*22, 23, 32*) and/or MAO-A (*33*).

Optical and PET detection of tau deposits in living tauopathy model mice

For assessing *in-vivo* interactions of PM-PBB3 with intracellular tau deposits, we utilized a murine transgenic (Tg) model of tauopathies dubbed rTg4510, which overexpresses a human four-repeat tau isoform with the P301L mutation causative of familial FTLD (*34, 35*). ^{18}F-PM-PBB3 bound to tau fibrils in homogenized forebrain tissues obtained from Tg with high affinity (K_D, 4.7 nM), while there was no homologously displaceable radioligand binding in non-transgenic (nTg) forebrain homogenates (Fig. 2a). *Ex-vivo* autoradiography of brain tissues collected from mice at 30 min after intravenous ^{18}F-PM-PBB3 injection demonstrated accumulations of the radioligand in the Tg forebrain harboring neuronal tau inclusions (Fig. 2b). Conversely, there was no noticeable increase of ^{18}F-PM-PBB3 retentions in the nTg forebrain (Fig 2b). In addition, the radioligand accumulation was minimal in the Tg and nTg cerebellum, which was devoid of tau pathologies (Fig 2b). Triple staining of brain sections used for *ex-vivo* autoradiography with PM-PBB3 fluorescence, GB, and AT8 illustrated strong binding of PM-PBB3 to intracellular tau aggregates in the hippocampus and neocortex of a Tg mouse (Fig 2c).

To assess the time course of *in-vivo* labeling of intraneuronal tau aggregates with PM-PBB3, we conducted intravital two-photon laser fluorescence microscopy with a cranial window to the somatosensory cortex of the Tg and nTg mice. Comparison of PM-PBB3 and PBB3 signals in the same field of view indicated rapid entry of these probes into the brain after intravenous probe administration, reaching tau aggregates within 5 min (Fig 2d). Quantification of the background-corrected fluorescence intensity revealed that PM-PBB3 yielded 3-fold higher peak fluorescence signals in the same neurons burdened with tau aggregate than PBB3 (Fig 2e). In contrast, no noticeable increases in fluorescence signals were produced by intravenously injected PM-PBB3 in neurons of nTg mice (Fig.

2d).

The *in-vivo* performance of ^{18}F-PM-PBB3 and ^{11}C-PBB3 as a PET probe was then

examined by a head-to-head comparison in the same mice (Fig. 2f-h). ^{18}F-PM-PBB3

rapidly entered the brain after intravenous administration, and the peak radioactivity

uptake was 1.4-fold higher than that of ^{11}C-PBB3 (Fig. 2g). This was followed by a

prompt washout of radioactivity from the brains of nTg mice, whereas the clearance was

retarded in the Tg forebrain, reflecting radioligand binding to tau deposits. ^{18}F-PM-PBB3

generated a more than 2-fold higher contrast for tau lesions in the Tg hippocampus

relative to nTg controls than ^{11}C-PBB3 (Fig 2h).

The high brain uptake and tau contrast by ^{18}F-PM-PBB3 versus ^{11}C-PBB3 were

primarily attributable to its stability against bio-metabolism, since unmetabolized [18]F-

PM-PBB3 accounted for 79.9% and 97.5% of the total radioactivity in plasma and brain,

respectively, in contrast to unchanged ^{11}C-PBB3 accounting for 2.5% and 72.4% of the

total radioactivity in plasma and brain, respectively, at 5 min after intravenous injection

(Table S1). ^{18}F-PM-PBB3 has been confirmed to be decomposed to a hydrophilic

radiometabolite in human plasma at a slower rate than metabolizing ^{11}C-PBB3 (Fig. S2)

(*15*).

High-contrast PET imaging of AD and PSP tau pathologies in humans enabled by

^{18}F-PM-PBB3

Encouraged by nonclinical results, ^{18}F-PM-PBB3 was applied to PET imaging in

human subjects. As depicted in Fig. 3a, the retention of ^{18}F-PM-PBB3 clearly visualized

the neocortical and limbic dominance of six tau isoform accumulations in an AD patient

and subcortical dominance of four-repeat tau depositions in a PSP patient with

Richardson's syndrome (PSP-Richardson), a PSP subcategory with a typical clinical

phenotype (*36*), in sharp contrast to the low radiosignals sustained in the parenchyma of

elderly healthy control (HC) brains. In fact, intensification of PET signals in the parieto-

temporal and posterior cingulate cortices of the AD brain and the subthalamic nucleus,

midbrain, and globus pallidus of the PSP brain was in agreement with the known

distribution of tau pathologies in these diseases (Fig. 3a).

The uptake of ^{18}F-PM-PBB3 peaked rapidly after radioligand injection and

subsequently declined by more than 50% across all regions of the HC brain in the next

30 min, resulting in uniformly low radioligand retention (Fig. 3b). The clearance of [18]F-

PM-PBB3 was profoundly slowed in tau-burdened areas of the AD and PSP brains,

conceivably reflecting the specific radioligand binding to tau aggregates (Fig. 3b). The

cerebellum was included in brain areas with the lowest radioactivity retention (Fig. 3b),

supporting the use of cerebellar gray matter as a reference tissue with a minimal tau fibril load for quantification of the radioligand binding. The target-to-reference ratio of the radioactivity (standardized uptake value ratio; SUVR) was progressively increased in affected brain areas until ~60 min after radioligand injection, and then it almost plateaued at ~90 min (Fig. 3c).

To examine the superiority of ^{18}F-PM-PBB3 to ^{11}C-PBB3 as a high-sensitivity tau PET probe, we carried out a head-to-head comparison of PET data with these radioligands in the same individuals. The peak uptake of ^{18}F-PM-PBB3 in the brain (Fig. 3b) was approximately 2-fold higher than that of ^{11}C-PBB3 (Fig. S3), and nonspecific radioactivity retentions in the basal ganglia and venous sinuses at high levels and several neocortical areas at low levels were provoked in a HC subject by ^{11}C-PBB3 but not ^{18}F-PM-PBB3 (Fig. 3a). Meanwhile, radioactivity accumulations in the choroid plexus, which were documented in the use of other tau radioligands including ^{18}F-flortaucipir (37-39), were augmented in ^{18}F-PM-PBB3-PET images as compared to PET data with ^{11}C-PBB3 (Fig. 3a). There was a significant correlation between regional SUVRs for ^{18}F-PM-PBB3 and ^{11}C-PBB3 in the cortical volumes of interest (VOIs) in the AD brain ($r = 0.679$, $p = 0.001$) and subcortical VOIs in the PSP brain ($r = 0.805$, $p < 0.001$) (Fig. 3d, e; see Fig. S4 for details of the VOI definition), and the linear regression slopes indicated that ^{18}F-PM-PBB3 produced more than 2-fold higher contrasts for AD and PSP tau deposits than ^{11}C-PBB3 (Fig. 3d, e).

As there was no significant correlation between SUVRs for ^{18}F-PM-PBB3 and ^{11}C-PiB in AD patients ($r = 0.295$, $p = 0.268$) (Fig.3f), it is unlikely that PET data with ^{18}F-PM-PBB3 can be considerably affected by its cross-reactivity with Aβ deposits.

The utility of ^{18}F-PM-PBB3 for PET assessments of the topology and stage of AD-spectrum and PSP tau pathologies

We performed tau and Aβ PET scans with ^{18}F-PM-PBB3 and ^{11}C-PiB, respectively, for three mild cognitive impairment (MCI) and 14 AD patients (mean age ± SD, 70.7 ± 11.9 years) as well as 23 HCs (mean age ± SD, 65.2 ± 7.9 years) in order to investigate the ability of ^{18}F-PM-PBB3 to capture the advancement of AD-spectrum tau pathologies in each individual. To this aim, we defined composite VOIs according to Braak's NFT stages (Fig. S4) (40, 41). The tau pathologies indicated by individual PET data were classified into stages zero (unaffected stage; 22 HCs), I/II (transentorhinal stage; one HC), III/IV (limbic stage; one MCI and three AD patient), and V/VI (neocortical stage; two MCI and 11 AD patients) by identifying Braak's stage composite VOIs with a regional Z score > 2.5. All HCs were negative for ^{11}C-PiB-PET, and all MCI and AD patients were positive

for ^{11}C-PiB-PET, judging from visual inspection of the acquired images. Representative ^{18}F-PM-PBB3-PET images demonstrated expansions of radiosignals from the medial temporal cortex to the other neocortical and limbic areas, along with progression of the NFT stage (Fig. 4a, b). ^{18}F-PM-PBB3 SUVRs in stage I/II VOI were elevated in a subset of HCs, being overlapped with the values in MCI and AD patients, and this may imply accumulations of tau fibrils in the medial temporal cortex at a preclinical stage of AD or PART (Fig. 4c). By contrast, SUVRs in stage III/IV and V/VI VOIs were much less variable among HCs, and all 17 AD-spectrum (MCI + AD) cases exhibited increased SUVR beyond the HC range in either of these VOIs (Fig. 4c). Moreover, the radioligand accumulation in stage V/VI VOI (Fig.4c) was significantly correlated with the severity of dementia as assessed by Clinical Dementia Rating Sum of Boxes (CDRSoB) ($r = 0.671$, $p = 0.003$) (Fig.4d), whereas other stage VOIs did not show significant correlations. These results indicate that ^{18}F-PM-PBB3 could detect tau depositions at preclinical and prodromal stages in the AD spectrum and PART and that the formation of ^{18}F-PM-PBB3-positive tau fibrils is intimately associated with functional deteriorations of neocortical neurons in subjects with cognitive declines.

The utility of ^{18}F-PM-PBB3 for evaluations of four-repeat tau pathologies was also examined in 16 PSP-Richardson patients who were negative for ^{11}C-PiB-PET (mean age ± SD, 71.5 ± 6.5 years). Severities of the disease in these cases were assessed using PSP Rating Scale (PSPRS), which is a sensitive measure to evaluate global disability, including the activity of daily living, motor, and mental disabilities, and to predict prognosis in clinical practice (*42*). High ^{18}F-PM-PBB3 retention was observed in the subthalamic nucleus and midbrain of PSP patients relative to HCs, was progressively intensified within these subcortical structures, and was expanded to the neocortical area, including the gray and white matter of the primary motor cortex together with increase in PSPRS scores (Fig.5a). Voxel-wise PET and magnetic resonance imaging (MRI) assays revealed high spatial accordance of the radioligand accumulation and brain atrophy in the subthalamic nucleus and midbrain as compared to HCs (Fig.5b). VOI-based analyses also showed significant elevations of the radioligand SUVRs in the subcortical areas of PSP patients compared to HCs (Fig.5c). In particular, SUVR in the subthalamic nucleus, which is one of the regions most severely affected by PSP tau pathologies (*43*), was increased in all PSP cases with little overlap with HC values (Fig. 5c), and was closely significantly correlated with PSPRS scores (Fig.5d) ($r = 0.566$, $p = 0.018$).

Intraindividual links between ^{18}F-PM-PBB3 PET data and tau pathologies in biopsy and autopsy brain tissues proven in CBD, PSP and PiD patients

We obtained histopathological evidence that *in-vivo* ^{18}F-PM-PBB3 binding reflects the
abundance of three- and four-repeat tau inclusions in patients with biopsy- and autopsy-
confirmed FTLD tauopathies. A clinical phenotype case of corticobasal syndrome (CBS)
underwent a brain biopsy to investigate the presence of a tumor in consideration of a low-
intensity lesion discovered by T1-weighted MRI as reported by Arakawa *et al*. (*44*) (Fig.
S5). Neuropathological and biochemical examinations of the biopsied sample from the
middle frontal gyrus revealed the presence of anti-four-repeat tau-specific antibody
(RD4) and/or GB positive astrocytic plaques, ballooned neurons, neuropil threads, and
coiled bodies resulting from the formation of insoluble four-repeat tau aggregates, which
are characteristic of CBD (*44*) (Fig. 6a). Subsequent PET scans of this case showed
negativity for ^{11}C-PiB and notable increases of ^{18}F-PM-PBB3 retentions in the primary
motor cortex, basal ganglia, and brainstem consistent with the regional localization of
CBD tau pathologies (*45*), and middle frontal gyrus (Fig. 6a and S5)
Brain autopsy was also performed for a PSP-Richardson patient who had received an
^{18}F-PM-PBB3 PET scan (see Supplemental Materials for clinical information), and a
definitive diagnosis of PSP (*46*) was made on the basis of neuropathological observations.
In-vivo ^{18}F-PM-PBB3 radiosignals in the brain parenchyma were primarily concentrated
in the subthalamic nucleus and midbrain (Figs. 3a, 5a (asterisked images), 6b and 7 (top
row)). Histochemical and immunohistochemical analyses of the autopsied specimen
identified a high abundance of GB- and AT8-stained tufted astrocytes in the tegmentum
and substantia nigra of the midbrain and subthalamic nucleus, and these tau inclusions
were fluorescently labeled with nonradioactive PM-PBB3 (Figs. 6b). In addition, GB-
positive tufted astrocytes were also distributed with high abundance in the globus pallidus
and lower abundance in the cerebral crus, internal capsule, and thalamus, which could
contribute to the subcortical PET signals (Figs. S6).
Moreover, we conducted brain autopsy of a patient with the clinical diagnosis of
behavioral variant frontotemporal dementia (bvFTD), who had undergone an ^{18}F-PM-
PBB3 PET scan (see Supplemental Materials for clinical information). Neuropathological
examinations of the autopsied tissues provided a definitive diagnosis of PiD (*46*).
Increased retentions of ^{18}F-PM-PBB3 were noticeable in frontal and temporal cortices,
but not in the occipital cortex (Fig. 6c). Histopathological assays showed numerous
intraneuronal Pick bodies along with neuropil threads were doubly labeled with AT8, and
PM-PBB3 fluorescence in the inferior frontal gyrus, in contrast to noticeable pathologies
in the primary visual cortex (Fig. 6c). Taken together, these data on imaging-pathology
relationships within a subject strongly support the capability of ^{18}F-PM-PBB3 for high-
contrast visualization of three- and four-repeat tau deposits in the FTLD spectrum.

Individual-based assessments of tau pathologies in living patients with diverse FTLD phenotypes

To test the feasibility of ^{18}F-PM-PBB3 for evaluations of FTLD tau pathologies on an individual basis, patients with diverse clinical FTLD phenotypes (see Supplemental Materials for clinical information) were scanned with this radioligand (Fig.7). The absence of overt AD pathologies was confirmed by the negativity for ^{11}C-PiB-PET in all these cases. As compared to a case included in the above-mentioned PSP-Richardson group (top row in Fig. 7), a patient with PSP parkinsonism (PSP-P), which is clinically characterized by mild motor disability relative to PSP-Richardson, showed a modestly increased tracer uptake confined to the subthalamic nucleus (second row in Fig. 7). A patient clinically diagnosed as non-AD CBS showed high radioligand binding in the primary motor cortex including below white matter and subcortical regions, such as the subthalamic nucleus, globus pallidus, and midbrain, with left-right asymmetry, which was predominant on the side contralateral to the more affected body side (third row in Fig. 7). These changes indicate the existence of CBD tau pathologies underlying the symptomatic manifestation of CBS. Similarly, left-side dominant enhancements of radioligand retention were observed in gray and white matter of the primary motor cortex (i. e. precentral gyrus), and subcortical structures of a patient with progressive non-fluent aphasia (PNFA) (fourth row in Fig. 7). It is accordingly probable that verbal symptoms in this individual represented by anarthria were chiefly attributable to CBD tau pathologies involving an inferior portion of the left precentral gyrus. Furthermore, a patient with bvFTD presented elevations of ^{18}F-PM-PBB3 uptake in the lateral superior frontal gyrus and prefrontal cortex with little involvement of the primary motor cortex and subcortical structures (bottom row in Fig. 7). Taken together, the tracer topographies matched with neuroanatomical variabilities of the FTLD spectrum, indicating that ^{18}F-PM-PBB3 could provide an accurate diagnosis based on the evaluation of pathological backgrounds on an individual basis.

In light of the current PET observations, we constructed a schematic map illustrating that the topology of ^{18}F-PM-PBB3 radiosignals is indicative of PSP, CBD, and PiD pathologies as bases of five different clinical phenotypes of FTLD (Fig. 8; clinicopathological relationships were modified from Williams and Lees, 2009 (*11*)). The subcortical dominance of tau depositions characterizes pathological changes in PSP, whereas a spatial expansion of areas with ^{18}F-PM-PBB3-positive tau lesions to neocortical gray and white matter centralized at the primary motor cortex may occur with disease progression. More widespread and intense accumulations in the neocortex, often

with left-right asymmetry, could suggest the presence of CBD pathologies provoking

clinical manifestations of CBS and PNFA. CBD tau abnormalities may also give rise to

bvFTD phenotypes but enhanced PET signals in the frontal and temporal cortices with

fewer involvements of the primary motor cortex and subcortical regions imply bvFTD

due to PiD pathologies. Hence, PET imaging with ^{18}F-PM-PBB3 potentially offers

identification of the tau neuropathology linked to the clinical features of FTLD in each

individual case.

DISCUSSION

Diagnostic evaluations of neurodegenerative tauopathies have been impeded by the

lack of one-to-one associations between diverse neuropathological and clinical

phenotypes. PET imaging with our novel radioligand, ^{18}F-PM-PBB3, has been proven to

capture a wide range of tau fibrils with different isoform compositions, conformations,

and ultrastructural dimensions with contrast and dynamic range adequate for individual-

based assessments of AD- and FLTD-spectrum syndromes. Of note is that imaging-

neuropathology relationships within single subjects undergoing biopsy or autopsy

provided compelling evidence for the ability of the present PET technology to detect tau

deposits in CBD, PSP, and PiD. In addition, sensitive detection of tau inclusions in a

tauopathy model mouse was enabled with a cellular scale by intravital two-photon laser

microscopy and non-labeled PM-PBB3 and with a regional scale by PET and ^{18}F-PM-

PBB3. This multi-scale imaging system could prove useful for non-clinical investigations

of neuropathologies, which can be combined with functional analyses exemplified by

microscopic calcium assays and macroscopic functional MRI to clarify links between tau

accumulations and neuronal dysfunctions from single-cell to brain-wide levels.

PBB derivatives exhibit unique features represented by high reactivity with three-

repeat or four-repeat tau assemblies in FTLD patients and mouse models (*15, 27*), in

contrast to weak *in-vitro* and *in-vivo* labeling of these aggregates with flortaucipir and its

'second-generation' analogs (*18, 25, 27*). One of the flortaucipir derivatives, ^{18}F-PI-2620,

was reported to react with four- and three-repeat tau inclusions in FTLD brains (*26, 47*),

but its capability to sensitively visualize FTLD-spectrum tau pathologies has been

controversial because of a lack of compelling evidence for the agreement of radioligand

retentions with PSP, CBD, and PiD tau topologies. PM-PBB3 was shown to more

efficiently enter the brain than the original compound, PBB3, primarily owing to its

higher stability against metabolic conversions. The substantial uptake of unmetabolized

PM-PBB3 in the brain resulted in the visualization of tau lesions with a high dynamic

range, which was more than 2-fold of the value yielded by PBB3 in human brains. Besides the pharmacokinetic properties, low retentions of radiosignals in venous sinuses and putative penetration vessels in the striatum facilitate the identification of pathological changes in the use of ^{18}F-PM-PBB3 as compared with ^{11}C-PBB3 (*15*). Moreover, ^{18}F-PM-PBB3 was not reactive with MAO-A and MAO-B and induced no increases in the striatal radioactivity related to MAO-B, unlike ^{18}F-THK5351 and allied quinoline derivatives (*22, 23*). This characteristic is also beneficial for tau PET imaging without off-target radioligand binding in MAO-B-expressing reactive astrocytes (*48*).

It is noteworthy that intensification and expansion of tau depositions in association with the progression of AD and PSP could be illustrated by ^{18}F-PM-PBB3 PET, indicating that this radioligand could illuminate tau species critically involved in deteriorations of neuronal functions. Similar to previous indications of prion-like tau dissemination in AD brains capturable by PET with other probes (*40, 49, 50*), ^{18}F-PM-PBB3 was capable of visualizing the spatial spread of tau depositions in line with Braak's tau staging, with regional radioligand retentions correlated with clinical advancements assessed by CDRSoB. Significantly, enhanced radiosignals in the subthalamic nucleus were concurrent with the symptomatic advancement of PSP scored by PSPRS and were expanded from subcortical to neocortical areas, seemingly in accordance with emergences of cognitive deficits. This observation may be attributable to the propagation of tau fibrillogenesis along with corticostriatal and corticothalamic connections, although prionoid properties of PSP-type tau will need to be proven by longitudinal PET tracking of tau aggregates in the same individuals.

The current data also provide evidence for the *in-vivo* performance of ^{18}F-PM-PBB3 as a diagnostic adjunct to the identification and differentiation of various clinical FTLD subtypes on a neuropathological basis. Indeed, distinctions between AD/PART and CBD/PSP in PNFA and CBS and among AD/PART, CBD/PSP, and PiD in bvFTD were allowed for each case according to the topology of PM-PBB3-positive tau deposits. Since these clear separations have not been possible with the use of previous tau PET ligands (*18, 51*) and other imaging modalities such as volumetric MRI, the current technology paves the way for the construction of a biomonitoring system for the selection of an adequate disease-modifying therapeutic. This advantage will be of particularly great importance for the development and implementation of treatments against glial deteriorations in consideration of astrocytic and oligodendrocytic tau accumulations that predominate PSP and CBD. It is yet to be clarified whether PSP and CBD are precisely differentiated in terms of regional distribution and laterality of PET-detectable tau lesions, notwithstanding the fact that these two disease categories occasionally display

considerable overlaps at clinical and neuropathological levels (*52*).

To date, the application of cryo-electron microscopy has led to the revelation that tau

filaments are constituted of a disease-specific self-assembling portion, providing intrinsic

binding pockets for PET ligands (*53, 54*). This diversity of the interaction between distinct

fibrils and ligands may not necessarily arise from differences in the tau isoform

composition but could stem from additional conformational variations. In fact, tau

assemblies in chronic traumatic encephalopathy (CTE) have been found to be composed

of a conformer distinct from the AD-type tau filament (*55*), despite the incorporation of

all six isoforms in both AD and CTE tau deposits. This could result in differential

affinities of tau PET probes for the two tau fibril species, and our pilot PET study has

demonstrated sensitive detection of CTE pathologies with ^{18}F-PM-PBB3 (Takahata et al.,

paper in preparation), which has not been achieved by ^{11}C-PBB3 (*56*) and flortaucipir (*57,*

58).

Along with technical benefits, several issues should also be considered regarding the

utilization of ^{18}F-PM-PBB3 in clinical PET scans. The accumulation of radioactivity in

the choroid plexus might hinder quantitative assessments of tau depositions in

neighboring structures, including the hippocampus, although this did not overtly

influence the measurement of radioligand retentions in the parahippocampal gyrus, which

is the area involved in tau pathologies at the earlies Braak stage. Radiosignals in the

choroid plexus were documented in previous works with several other tau radioligands

(*38, 59*) and are likely derived from compounds bound to Biondi bodies mainly composed

of non-tau but yet unidentified proteins (*37, 38*). Another caveat might be

photoisomerization of PM-PBB3, which is similar to the reported property of PBB3 (*28*).

Our data indicated that the conversion of PBB3 and PM-PBB3 to their isomers could be

entirely blocked using a UV-free LED light in the radiosynthesis and administration to

subjects, requiring small additional equipment in nuclear medicine facilities.

The translational research workflow with PM-PBB3 offers a seamless evaluation of

candidate anti-tau therapeutics (*60, 61*) in non-clinical and subsequent clinical settings.

Comparisons between efficacies of such potential drugs in animal models and humans

with the same imaging-based biomarker will also help refine these models in view of their

resemblance to tauopathy cases.

Conclusion

The new bimodal imaging agent, PM-PBB3, enabled high-contrast optical and PET

detection of diverse tau conformers at cellular, regional, and global scales in animal brains.

This probe also captured AD- and FTLD-type tau pathologies with a dynamic range

sufficient for differentiation and staging of tauopathy subtypes in each subject, reinforcing

investigations of the neuropathological basis of clinical phenotypes in living tauopathy

cases.

MATERIALS AND METHODS

Compounds and Antibodies

PM-PBB3 1-fluoro-3-((2-((1E,3E)-4-(6-(methylamino)pyridine-3-yl)buta-1,3-dien-1-

yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol (Fig. 1a) and tosylate precursor of ^{18}F-PM-

PBB3 protected with tert-Butyloxycarbonyl group and 2-tetrahydropyranyl group (Fig.

S1) were custom-synthesized (Nard Institute). The precursor of ^{18}F-PM-PBB3 was also

provided by APRINOIA Therapeutics Inc. PBB3 (2-((1E,3E)-4-(6-

(methylamino)pyridine-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol) (Fig. 1a) and

desmethyl precursor of ^{11}C-PBB3 were also custom-synthesized (Nard Institute) (*15*).

The reference standard for ^{11}C-PiB, 6-OH-BTA-1, is commercially available (ABX), and

the desmethyl precursor of ^{11}C-PiB protected with methoxymethyl group, 6-MOMO-

BTA-0, was custom-synthesized (KNC Laboratories). PBB5 (*15*), BTA-1, clorgiline and

selegiline are commercially available (Sigma-Aldrich). A monoclonal antibody against

tau phosphorylated at Ser 202 and Thr 205 (AT8, Endogen) and four-repeat tau isoform

(RD4, Upstate) are commercially available.

Postmortem brain tissues

Postmortem human brains were obtained from autopsies carried out at the Center for

Neurodegenerative Disease Research of the University of Pennsylvania Perelman School

of Medicine on patients with AD, PiD, PSP and CBD, and at the Department of Neurology

at the Chiba-East National Hospital on patients with PSP. Tissues for homogenate binding

assays were frozen, and tissues for histochemical, immunohistochemical and

autoradiographic labeling were frozen or fixed in 10% neutral buffered formalin followed

by embedding in paraffin blocks.

Mice

The parental P301L tau responder line, parental tTA activator line, and the resultant F1

rTg4510 mice and littermates were generated and maintained as previously described

(*35, 62*). All mice studied here were maintained and handled in accordance with the

National Research Council's Guide for the Care and Use of Laboratory Animals.

Protocols for the present animal experiments were approved by the Animal Ethics Committees of the National Institute of Radiological Science. All procedures involving live mice received prior approval from the Institutional Animal Care and Use Committee of the University of Florida.

Radiosynthesis

[11]C-PBB3 was radiosynthesized using its desmethyl precursor, as the method previously described (*15*). Radiolabeling of ^{18}F-PM-PBB3 was performed as the synthetic pathway described in Fig. S1. Tosylate precursor of ^{18}F-PM-PBB3 was reacted with ^{18}F-fluoride in the presence of dimethyl sulfoxide, K_2CO_3 and and K222 at 110°C for 15 min. After cooling the reaction vessel to 90°C, hydrochloric acid was added to the mixture and maintained for 10 min to delete the protecting groups. Sodium acetate was added to the reaction vessel, and the radioactive mixture was transferred into a reservoir for high-performance liquid chromatography (HPLC) purification (Waters Atlantis prep T3 column, 10 × 150 mm; CH_3CN/50 mM $AcONH_4$ = 4/6, 5 ml/min). The fraction corresponding to ^{18}F-PM-PBB3 was collected in a flask containing 25% ascorbic acid solution and Tween 80, and was evaporated to dryness under a vacuum. The residue was dissolved in 17 ml of saline (pH 7.4) to obtain ^{18}F-PM-PBB3 as an injectable solution. The final formulated product was radiochemically pure ($\geq$ 95%) as detected by analytic HPLC (Waters Atlantis prep T3 column, 4.6 × 150 mm; CH_3CN/50 mM $AcONH_4$ = 4/6, 1 ml/min). The specific activity of ^{18}F-PM-PBB3 at the end of synthesis was 58-761 GBq/μmol, and ^{18}F-PM-PBB3 maintained its radioactive purity exceeding 90% for over 3 hr after formulation. Radiolabelling of ^{11}C-PiB was performed as previously described (*63*).

PBB3 is known to undergo photo-isomerization under ordinary fluorescent light (*28*). ^{18}F-PM-PBB3 and ^{11}C-PBB3 in a colorless vial were isomerized by exposure to the fluorescent light for 30 min (Fig. S7a and b, left). UV-VIS absorption spectra for PM-PBB3 and PBB3 indicated that these compounds do not absorb light with wavelength longer than 500 nm (Fig. S7c). Then, ^{18}F-PM-PBB3 and ^{11}C-PBB3 in a colorless vial were placed under a UV-cut light (<500 nm wavelength cutoff, ECOHiLUX HES-YF, 2200 lm, Iris Oyama Inc.) for 30 min, and both compounds were found to be stable under this condition (Fig. S7a and b, right). Based on these results, radiosyntheses of ^{18}F-PM-PBB3 and ^{11}C-PBB3 and all experiments with these compounds were performed under the UV-cut light to avoid photo-isomerization of these compounds.

***In vitro* and *ex vivo* autoradiography**

In vitro autoradiography was performed using 6-µm-thick deparaffinized sections derived from AD and 20-µm-thick fresh frozen sections post-fixed in 4% paraformaldehyde solution derived from PSP brains. For labeling with ^{18}F-PM-PBB3, sections were pre-incubated in 50 mM Tris-HCl buffer, pH 7.4, containing 20% ethanol at room temperature for 30 min, and incubated in 50 mM Tris-HCl buffer, pH 7.4, containing 20% ethanol and 5 nM of ^{18}F-PM-PBB3 (specific radioactivity: 58 GBq/µmol) at room temperature for 60 min. The samples were then rinsed with ice-cold Tris-HCl buffer containing 20% ethanol twice for 2 min, and dipped into ice-cold water for 10 sec. For *ex vivo* autoradiography, Tg and nTg wild type at 9.7 months of age were anesthetized with 1.5% (v/v) isoflurane and given 33.3 MBq ^{18}F-PM-PBB3 (specific radioactivity: 248.4 GBq/µmol) by syringe via tail vein. The animals were killed by decapitation at 30 min after tracer administration. Brain was harvested and cut into 20-µm-thick sections on a cryostat (HM560; Thermo Fisher Scientific).

The sections labeled with ^{18}F-PM-PBB3 were subsequently dried by treating with warm air, and exposed to an imaging plate (BAS-MS2025, Fuji Film). The imaging plate was scanned with a BAS-5000 system (Fuji Film) to acquire autoradiograms. Fresh frozen sections generated in the process of *ex vivo* autoradiography were post-fixed in 4% paraformaldehyde solution for the subsequent histological examination.

Histological examination

For fluorescence labeling, deparaffinized sections and sections used for autoradiography were incubated in 50% ethanol containing 25 µM of non-radiolabeled PM-PBB3 at room temperature for 30 min. The samples were rinsed with 50% ethanol for 5 min, dipped into distilled water twice for 3 min, and mounted in non-fluorescent mounting media (VECTASHIELD, Vector Laboratories). Fluorescence images were captured using a DM4000 microscope (Leica) equipped with a custom filter cube for PBB3 (excitation band-pass at 414/46 nm and suppression low-pass with 458 nm cutoff) (*27*). Following microscopy, sections were autoclaved for antigen retrieval, and immunostained with AT8. Immunolabeling was then examined using DM4000. Finally, the tested samples were used for GB staining with Nuclear Fast Red (Sigma-Aldrich) counter-staining after pretreatment with 0.25% $KMnO_4$ followed by 2% oxalic acid.

In vivo **two-photon fluorescence microscopy**

Two weeks before the measurement, surgery to create cranial windows was performed. For this procedure, the animals were anesthetized with a mixture of air, oxygen, and isoflurane (3-5% for induction and 2% for surgery) via a facemask, and a cranial window

(3-4 mm in diameter) was attached over the left somatosensory cortex, centered at 1.8

mm caudal and 2.5 mm lateral from the bregma, according to the 'Seylaz-Tomita method'

(*64*). A custom metal plate was affixed to the skull with a 7-mm-diameter hole centered

over the cranial window.

Sulforhodamine 101 (MP Biomedicals) dissolved in saline (10 mM) was injected

intraperitoneally (8 µl/g body weight) just before initiation of the imaging experiments.

The awake animals were placed on a custom-made apparatus, and real-time imaging was

conducted by two-photon laser-scanning microscopy (TCS-SP5 MP, Leica) with an

excitation wavelength of 900 nm. Two-photon imaging was performed before and 5, 30,

60, 90 and 120 min after intravenous injection of 0.05 mg of PM-PBB3 and PBB3

dissolved in dimethyl sulfoxide : saline = 1 : 1 (0.05% W/V). An emission signal was

separated by a beam splitter (560/10 nm) and simultaneously detected through a band-

pass filter for sulforhodamine 101 (610/75 nm) and PM-PBB3 and PBB3 (525/500 nm).

A single image plane consisted of 1024 by 1024 pixels, and in-plane pixel-size was 0.25–

0.45µm depending on an instrumental zoom factor. Images were acquired at a depth of

0.2–0.4 mm from the cortical surface. In each resulting images from Tg mouse,

fluorescence intensity from 10 randomly selected fluorescence-labeled pathologies were

measured by ImageJ, and the average was calculated after background normalization. It

should be noted that the background intensity of each image was acquired by averaging

the fluorescence intensity at 10 randomly selected areas where no fluorescence-labeled

pathologies were found.

In vivo PET imaging in mice

PET scans were performed using a microPET Focus 220 animal scanner (Siemens

Healthcare) providing 95 transaxial slices 2.0 mm (center-to-center) apart, a 19.0-cm

transaxial field of view (FOV), and a 7.6-cm axial FOV. Prior to the scans, Tg and nTg

mice at 8-9 months of age (n = 3 each) were anesthetized with 1.5% (v/v) isoflurane.

Emission scans were carried out for 90 min (^{18}F-PM-PBB3) or 60 min (^{11}C-PBB3) in 3D

list mode with an energy window of 350-750 keV, immediately after intravenous injection

of ^{18}F-PM-PBB3 (28.3 ± 10.3 MBq) or ^{11}C-PBB3 (29.7 ± 9.3 MBq). All list-mode data

were sorted into 3D sinograms, which were then Fourier-rebinned into 2D sinograms

(frames for ^{18}F-PM-PBB3: 4 × 1, 8 × 2, and 14 × 5 min, frames for ^{11}C-PBB3: 10 × 1, 6

× 5, and 2 × 10 min). Average images were generated with maximum *a posteriori*

reconstruction, and dynamic images were reconstructed with filtered backprojection

using a 0.5-mm Hanning filter. VOIs of hippocampus and cerebellum were placed using

PMOD image analysis software (PMOD Technologies Ltd) with reference to the

individual MR image.

***In vitro* binding assay**

Frozen tissues derived from the frontal cortex of an AD patient, the motor cortex of a

PSP patient and the forebrain of Tg and nTg mice were homogenized in 50 mM Tris-

HCl buffer, pH 7.4, containing protease inhibitor cocktail (cOmplete[TM], EDTA-free,

Roche), and stored at -80°C pending analyses. To assay radioligand binding with

homologous or heterologous blockade, these homogenates (100 μg tissue) were

incubated with 1 nM ^{18}F-PM-PBB3 (specific radioactivity: 257.2 ± 22.2 GBq/μmol) in

the presence or absence of non-radiolabeled PM-PBB3, BTA-1, clorgiline and selegiline

at varying concentrations ranging from 10^{-11}-10^{-6} M in Tris-HCl buffer containing 10%

ethanol, pH 7.4, for 30 min at room temperature. Non-specific binding of ^{18}F-PM-PBB3

was determined in the presence of 5×10^{-7} M PM-PBB3. Samples were run in

quadruplicates and specific radioligand binding was determined as pmol/g tissue. Ki was

determined by using non-linear regression to fit a concentration-binding plot to one-site

binding models derived from the Cheng-Prusoff equation with GraphPad Prism version

5.0 (GraphPad Software), followed by F-test for model selection. Kd and Bmax were

calculated from homologous competitive binding using this function:

$Kd = Ki = IC50 - [Radioligand]$

$Bmax = \frac{Top-Bottom}{[Radioligand]/(Kd+[Radioligand])}$

where IC50 and [Radioligand] are concentration of the competitor inducing 50%

inhibition and radiotracer concentration, respectively, and Top and Bottom are upper and

lower plateaus of the plot curve, respectively.

Human subjects

We included 23 HCs and 39 patients with diverse tauopathies - AD and FTLD spectrum

in the present study. All HCs were without a history of neurologic and psychiatric

disorders. Three MCI patients and 14 AD patients met Petersen's criteria (*65*) and

NINDS-ADRDA criteria, respectively (*66*). Seventeen PSP patients were clinically

diagnosed according to the Movement Disorder Society new diagnostic criteria (*36*) and

classified into each clinical variant: 16 PSP-Richardson and one PSP-P. Five other FTLD

spectrum; two CBS, one PNFA and two bvFTD, were also diagnosed according to

established criteria (*67-69*). In the present study, HCs and FTLD spectrum patients

required PiB (-) to exclude preclinical and co-pathological AD, whereas MCI and AD

patients needed PiB (+) by visual assessment. In addition, diagnoses of some patients

were also validated according to their neuropathological examinations. One CBS patient was confirmed with CBD according to brain tissue biopsy before the PET scan (*44*); each of the PSP-Richardson and bvFTD patients was also neuropathologically diagnosed as PSP and PiD (*46*) by autopsies after two years and one year after each PET scan, respectively.

Written informed consents were obtained from all subjects and/or from spouses or other close family members when subjects were cognitively impaired. This study was approved by the Radiation Drug Safety Committee and National Institutes for Quantum and Radiological Science and Technology Certified Review Board of Japan. The study was registered with UMIN Clinical Trials Registry (UMIN-CTR; number 000030248).

***In vivo* MRI and PET Imaging in Human Subjects**

MR images were acquired with a 3-T scanner, MAGNETOM Verio (Siemens Healthcare). Three-dimensional volumetric acquisition of a T1-weighted gradient echo sequence produced a gapless series of thin sagittal sections (TE = 1.95 ms, TR = 2300 ms, TI = 900 ms, flip angle = 9°, acquisition matrix = 256×256×250, voxel size=1×1×1mm). PET assays were conducted with a Biograph mCT flow system (Siemens Healthcare), which provides 109 sections with an axial field of view of 16.2 cm. The intrinsic spatial resolution was 5.9 mm in-plane and 5.5 mm full-width at half-maximum axially. Images were reconstructed using a filtered back projection algorithm with a Hanning filter (4.0 mm full-width at half-maximum).

^{18}F-PMPBB3 had an average injected dose of 189.5 ± 22.5 MBq with a molar activity at the time of injection of 238.5 ± 71.8 GBq/μmol. ^{18}F-PM-PBB3 PET scans were performed with two steps of scan protocol. Of the first protocol, dynamic PET scans with arterial blood sampling were performed with two imaging sessions of 60 min each with a 30 min break between sessions (0–60 and 90-150 min). The dynamic scan consisted of 12×10 s, 2×30 s, 7×1 min, 1×2 min, 1×3 min, 3×5 min, 3×6 min for the initial 60-min session, and 6×10-min frames for the second 60-min session. Of the second protocol, a 20-min PET acquisition was performed 90 min after injections (4×5-min frames) (see also Supplemental Materials).

^{11}C-PBB3 and ^{11}C-PiB PET scans were performed following a previously reported protocol (*15, 29, 49*). Seventy-minute dynamic PET scans were performed after an intravenous injection of ^{11}C-PBB3 (injected dose: 423.1 ± 57.2 MBq, molar activity: 70.0 ± 18.6 GBq/ μmol). ^{11}C-PiB (injected dose: 521.2 ± 87.3 MBq, molar activity: 81.8 ± 40.5 GBq/ μmol) PET scan was conducted with a 20-min acquisition 50 min after

injections; a ECAT EXACT HR+ scanner (CTI PET Systems, Inc.) was also utilized for

^{11}C-PiB alternatively.

Image analyses in Human Subjects

Data preprocessing was performed using PMOD 3.8 and Statistical Parametric

Mapping software (SPM12, Wellcome Department of Cognitive Neurology). Acquired

PET images were rigidly coregistered to individual T1-weighted MR images. SUVR

images were generated from averaged PET images at the following intervals: 30-50 min

(^{11}C-PBB3), 50-70 min (^{11}C-PiB) and 90-110 min (^{18}F-PM-PBB3) post injection,

respectively. Cerebellar gray matter was used as reference region. Regarding VOI

analyses, surface-based cortical reconstruction was conducted with FreeSurfer 6.0

(http://surfer.nmr.mgh.harvard.edu/) from the Desikan–Killiany–Tourville atlas (*70*), and

then cortical and Braak-staging VOIs were generated. Subcortical VOIs were transformed

from a template atlas (Talairach Daemon atlas from the Wake Forest University PickAtlas

version 3.0.5) to each native space using the deformation field obtained from the tissue-

class segmentation of SPM12. Regarding voxel-wise analysis, each image was spatially

normalized to MNI (Montreal Neurologic Institute) space using Diffeomorphic

Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) algorithm.

Subsequently, normalized images were smoothed with a Gaussian kernel with an 8-mm

full-width at half-maximum. Partial volume correction was not performed in the present

study.

Characteristics of ^{18}F-PM-PBB3 in Human Subjects

We explored uptake into the brain, and the dynamic range and distribution of specific

binding of ^{18}F-PM-PBB3. A head-to-head comparison of ^{18}F-PM-PBB3, ^{11}C-PBB3 and

^{11}C-PiB was conducted in the same individuals. Regional time-activity curves as

standardized uptake value (SUV) and SUVR were generated over the time course of the

dynamic scan; in addition, linear regression analyses were performed among the regional

SUVR of each tracer derived from the same subjects. For AD, VOIs were set in each lobe

of the cerebral cortex to compare the dynamic range and distribution of specific binding

among the three tracers. For PSP, the same number of VOIs as for AD were set to compare

the dynamic range among PBB3 compounds in the subcortical structures where PSP is

considered to show moderate to high tau burden (*71*) - globus pallidus, substantia nigra,

red nucleus, and subthalamic nucleus. Besides, the midbrain was also used as a broad

target-region for PSP (Fig. S4).

Assessing Tau Deposits Associated with AD

Progression of tau deposits in HCs, MCI and AD patients were evaluated according to the image-based tau stage. We calculated SUVRs and Z scores of composite VOIs based on Braak's pathological stages of neurofibrillary tangle: stages Ⅰ/Ⅱ (transentorhinal), Ⅲ/Ⅳ (limbic) and Ⅴ/Ⅵ (neocortical) (*40, 41*). Hippocampus was excluded from the analysis because of contamination of the signal from off-target binding in the choroid plexus. The stage showing highest regional Z score > 2.5 was assigned to the individual image-based tau stage: subjects showing lack of involvement of stages Ⅰ/Ⅱ were classified as stages zero. Subsequently, we assessed distribution of tau deposits and clinical association in each image-based tau stage. Voxel-level comparisons were performed comparing stages Ⅰ/Ⅱ, Ⅲ/Ⅳ and Ⅴ/Ⅵ to stage zero. Group comparisons between MCI/AD patients and HCs were also performed in each VOI; in addition, regression analyses between SUVR of each VOI and CDRSoB were also performed in MCI and AD patients.

Assessing Tau Deposits Associated with PSP-Richardson

Associations among tau deposits, clinical symptoms and brain atrophy were assessed. Brain atrophy was estimated by voxel-based morphometry. Voxel-level comparisons between PSP-Richardson patients and HCs were performed regarding distributions of tau deposits and brain atrophy. Group comparisons using subcortical VOIs were also conducted; in addition, regression analyses between SUVR of each VOI and PSPRS scores were also performed in PSP-Richardson patients.

Statistical Analyses in Human Subjects

Statistical calculations with respect to VOI analyses were performed using GraphPad Prism 7.0. Group comparisons of SUVR values derived from VOIs between HCs and MCI/AD or PSP-Richardson groups were conducted by two-sample t-test. Pearson correlation and linear regression analyses were conducted in a head-to-head comparison among the respective tracers. Clinical associations were also explored by Pearson correlation analysis. Furthermore, voxel-wise analyses were conducted by SPM12; we used the two-sample t-test model of SPM12 for group comparisons. The extent threshold was set to the expected voxels per cluster. For multiple voxel comparisons, family-wise error corrections at cluster levels were applied ($p < 0.05$). All P values are shown in the figures or their legends.

SUPPLEMENTAL MATERIALS

Material and Methods

REFERENCES AND NOTES

1.   L. C. Walker, M. Jucker, Neurodegenerative diseases: expanding the prion concept. *Annu Rev Neurosci* **38**, 87-103 (2015).

2.   C. Soto, S. Pritzkow, Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. *Nat Neurosci* **21**, 1332-1340 (2018).

3.   M. G. Spillantini, M. Goedert, Tau pathology and neurodegeneration. *Lancet Neurol* **12**, 609-622 (2013).

4.   K. Iqbal, F. Liu, C. X. Gong, Tau and neurodegenerative disease: the story so far. *Nat Rev Neurol* **12**, 15-27 (2016).

5.   L. Buee, T. Bussiere, V. Buee-Scherrer, A. Delacourte, P. R. Hof, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev* **33**, 95-130 (2000).

6.   V. M. Lee, M. Goedert, J. Q. Trojanowski, Neurodegenerative tauopathies. *Annu Rev Neurosci* **24**, 1121-1159 (2001).

7.   A. W. P. Fitzpatrick, B. Falcon, S. He, A. G. Murzin, G. Murshudov, H. J. Garringer, R. A. Crowther, B. Ghetti, M. Goedert, S. H. W. Scheres, Cryo-EM structures of tau filaments from Alzheimer's disease. *Nature* **547**, 185-190 (2017).

8.   B. Falcon, W. Zhang, A. G. Murzin, G. Murshudov, H. J. Garringer, R. Vidal, R. A. Crowther, B. Ghetti, S. H. W. Scheres, M. Goedert, Structures of filaments from Pick's disease reveal a novel tau protein fold. *Nature* **561**, 137-140 (2018).

9.   S. L. Forrest, J. J. Kril, G. M. Halliday, Cellular and regional vulnerability in

frontotemporal tauopathies. *Acta Neuropathol* **138**, 705-727 (2019).

10. G. D. Rabinovici, B. L. Miller, Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. *CNS Drugs* **24**, 375-398 (2010).

11. D. R. Williams, A. J. Lees, Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. *Lancet Neurol* **8**, 270-279 (2009).

12. W. Zhang, A. Tarutani, K. L. Newell, A. G. Murzin, T. Matsubara, B. Falcon, R. Vidal, H. J. Garringer, Y. Shi, T. Ikeuchi, S. Murayama, B. Ghetti, M. Hasegawa, M. Goedert, S. H. W. Scheres, Novel tau filament fold in corticobasal degeneration. *Nature*, (2020).

13. R. Harada, N. Okamura, S. Furumoto, K. Furukawa, A. Ishiki, N. Tomita, T. Tago, K. Hiraoka, S. Watanuki, M. Shidahara, M. Miyake, Y. Ishikawa, R. Matsuda, A. Inami, T. Yoshikawa, Y. Funaki, R. Iwata, M. Tashiro, K. Yanai, H. Arai, Y. Kudo, 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. *J Nucl Med* **57**, 208-214 (2016).

14. D. T. Chien, A. K. Szardenings, S. Bahri, J. C. Walsh, F. Mu, C. Xia, W. R. Shankle, A. J. Lerner, M. Y. Su, A. Elizarov, H. C. Kolb, Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. *J Alzheimers Dis* **38**, 171-184 (2014).

15. M. Maruyama, H. Shimada, T. Suhara, H. Shinotoh, B. Ji, J. Maeda, M. R. Zhang, J. Q. Trojanowski, V. M. Lee, M. Ono, K. Masamoto, H. Takano, N. Sahara, N. Iwata, N. Okamura, S. Furumoto, Y. Kudo, Q. Chang, T. C. Saido, A. Takashima, J. Lewis, M. K. Jang, I. Aoki, H. Ito, M. Higuchi, Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. *Neuron* **79**, 1094-1108 (2013).

16. H. Shimada, S. Kitamura, H. Shinotoh, H. Endo, F. Niwa, S. Hirano, Y. Kimura, M. R. Zhang, S. Kuwabara, T. Suhara, M. Higuchi, Association between Abeta and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [(11)C]PBB3-PET study. *Alzheimers Dement (Amst)* **6**, 11-20 (2017).

17. N. Okamura, T. Suemoto, S. Furumoto, M. Suzuki, H. Shimadzu, H. Akatsu, T. Yamamoto, H. Fujiwara, M. Nemoto, M. Maruyama, H. Arai, K. Yanai, T. Sawada, Y. Kudo, Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. *J Neurosci* **25**, 10857-10862 (2005).

18. D. R. Schonhaut, C. T. McMillan, S. Spina, B. C. Dickerson, A. Siderowf, M. D. Devous, Sr., R. Tsai, J. Winer, D. S. Russell, I. Litvan, E. D. Roberson, W. W. Seeley, L. T. Grinberg, J. H. Kramer, B. L. Miller, P. Pressman, I. Nasrallah, S. L. Baker, S. N. Gomperts, K. A. Johnson, M. Grossman, W. J. Jagust, A. L. Boxer, G. D. Rabinovici,

(18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. *Ann Neurol* **82**, 622-634 (2017).

19. H. Endo, H. Shimada, N. Sahara, M. Ono, S. Koga, S. Kitamura, F. Niwa, S. Hirano, Y. Kimura, M. Ichise, H. Shinotoh, M. R. Zhang, S. Kuwabara, D. W. Dickson, T. Toda, T. Suhara, M. Higuchi, In vivo binding of a tau imaging probe, [(11) C]PBB3, in patients with progressive supranuclear palsy. *Mov Disord* **34**, 744-754 (2019).

20. A. Kikuchi, N. Okamura, T. Hasegawa, R. Harada, S. Watanuki, Y. Funaki, K. Hiraoka, T. Baba, N. Sugeno, R. Oshima, S. Yoshida, J. Kobayashi, M. Ezura, M. Kobayashi, O. Tano, S. Mugikura, R. Iwata, A. Ishiki, K. Furukawa, H. Arai, S. Furumoto, M. Tashiro, K. Yanai, Y. Kudo, A. Takeda, M. Aoki, In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. *Neurology* **87**, 2309-2316 (2016).

21. M. Brendel, S. Schonecker, G. Hoglinger, S. Lindner, J. Havla, J. Blautzik, J. Sauerbeck, G. Rohrer, C. Zach, F. Vettermann, A. E. Lang, L. Golbe, G. Nubling, P. Bartenstein, K. Furukawa, A. Ishiki, K. Botzel, A. Danek, N. Okamura, J. Levin, A. Rominger, [(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. *Front Aging Neurosci* **9**, 440 (2017).

22. R. Harada, A. Ishiki, H. Kai, N. Sato, K. Furukawa, S. Furumoto, T. Tago, N. Tomita, S. Watanuki, K. Hiraoka, Y. Ishikawa, Y. Funaki, T. Nakamura, T. Yoshikawa, R. Iwata, M. Tashiro, H. Sasano, T. Kitamoto, K. Yanai, H. Arai, Y. Kudo, N. Okamura, Correlations of (18)F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer's disease. *J Nucl Med*, (2017).

23. K. P. Ng, T. A. Pascoal, S. Mathotaarachchi, J. Therriault, M. S. Kang, M. Shin, M. C. Guiot, Q. Guo, R. Harada, R. A. Comley, G. Massarweh, J. P. Soucy, N. Okamura, S. Gauthier, P. Rosa-Neto, Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. *Alzheimers Res Ther* **9**, 25 (2017).

24. M. Honer, L. Gobbi, H. Knust, H. Kuwabara, D. Muri, M. Koerner, H. Valentine, R. F. Dannals, D. F. Wong, E. Borroni, Preclinical Evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. *J Nucl Med* **59**, 675-681 (2018).

25. C. Aguero, M. Dhaynaut, M. D. Normandin, A. C. Amaral, N. J. Guehl, R. Neelamegam, M. Marquie, K. A. Johnson, G. El Fakhri, M. P. Frosch, T. Gomez-Isla, Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. *Acta Neuropathol Commun* **7**, 37 (2019).

26. H. B. Matthias Brendel, Thilo Van Eimeren, Kenneth Marek, Leonie Beyer,

Mengmeng Song, Carla Palleis, Jochen Hammes, Dorothee Saur, Matthias Schroeter, Jost-Julian Rumpf, Michael Rullmann, Andreas Schildan, Marianne Patt, Jennifer Madonia, David Russell, Andrew Stephens, Sigrun Roeber, Johannes Levin, Joseph Classen, Guenter Hoeglinger, Peter Bartenstein, Alexander Drzezga, John Seibyl, and Osama Sabri, 18F-PI2620 Tau-PET in Progressive Supranuclear Palsy - A multi-center evaluation. *J Nucl Med* **60**, 54 (2019).

27. M. Ono, N. Sahara, K. Kumata, B. Ji, R. Ni, S. Koga, D. W. Dickson, J. Q. Trojanowski, V. M. Lee, M. Yoshida, I. Hozumi, Y. Yoshiyama, J. C. van Swieten, A. Nordberg, T. Suhara, M. R. Zhang, M. Higuchi, Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. *Brain* **140**, 764-780 (2017).

28. H. Hashimoto, K. Kawamura, N. Igarashi, M. Takei, T. Fujishiro, Y. Aihara, S. Shiomi, M. Muto, T. Ito, K. Furutsuka, T. Yamasaki, J. Yui, L. Xie, M. Ono, A. Hatori, K. Nemoto, T. Suhara, M. Higuchi, M. R. Zhang, Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. *J Nucl Med* **55**, 1532-1538 (2014).

29. Y. Kimura, M. Ichise, H. Ito, H. Shimada, Y. Ikoma, C. Seki, H. Takano, S. Kitamura, H. Shinotoh, K. Kawamura, M. R. Zhang, N. Sahara, T. Suhara, M. Higuchi, PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. *J Nucl Med* **56**, 1359-1365 (2015).

30. W. E. Klunk, Y. Wang, G. F. Huang, M. L. Debnath, D. P. Holt, C. A. Mathis, Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. *Life Sci* **69**, 1471-1484 (2001).

31. R. Ni, B. Ji, M. Ono, N. Sahara, M. R. Zhang, I. Aoki, A. Nordberg, T. Suhara, M. Higuchi, Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. *J Nucl Med* **59**, 960-966 (2018).

32. L. Lemoine, A. Leuzy, K. Chiotis, E. Rodriguez-Vieitez, A. Nordberg, Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. *Alzheimers Dement (Amst)* **10**, 232-236 (2018).

33. C. Vermeiren, P. Motte, D. Viot, G. Mairet-Coello, J. P. Courade, M. Citron, J. Mercier, J. Hannestad, M. Gillard, The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. *Mov Disord*, (2017).

34. N. Sahara, P. D. Perez, W. L. Lin, D. W. Dickson, Y. Ren, H. Zeng, J. Lewis, M. Febo, Age-related decline in white matter integrity in a mouse model of tauopathy: an in vivo diffusion tensor magnetic resonance imaging study. *Neurobiol Aging* **35**, 1364-

1374 (2014).

35. K. Santacruz, J. Lewis, T. Spires, J. Paulson, L. Kotilinek, M. Ingelsson, A. Guimaraes, M. DeTure, M. Ramsden, E. McGowan, C. Forster, M. Yue, J. Orne, C. Janus, A. Mariash, M. Kuskowski, B. Hyman, M. Hutton, K. H. Ashe, Tau suppression in a neurodegenerative mouse model improves memory function. *Science* **309**, 476-481 (2005).

36. G. U. Hoglinger, G. Respondek, M. Stamelou, C. Kurz, K. A. Josephs, A. E. Lang, B. Mollenhauer, U. Muller, C. Nilsson, J. L. Whitwell, T. Arzberger, E. Englund, E. Gelpi, A. Giese, D. J. Irwin, W. G. Meissner, A. Pantelyat, A. Rajput, J. C. van Swieten, C. Troakes, A. Antonini, K. P. Bhatia, Y. Bordelon, Y. Compta, J. C. Corvol, C. Colosimo, D. W. Dickson, R. Dodel, L. Ferguson, M. Grossman, J. Kassubek, F. Krismer, J. Levin, S. Lorenzl, H. R. Morris, P. Nestor, W. H. Oertel, W. Poewe, G. Rabinovici, J. B. Rowe, G. D. Schellenberg, K. Seppi, T. van Eimeren, G. K. Wenning, A. L. Boxer, L. I. Golbe, I. Litvan, P. S. P. S. G. Movement Disorder Society-endorsed, Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord* **32**, 853-864 (2017).

37. V. J. Lowe, G. Curran, P. Fang, A. M. Liesinger, K. A. Josephs, J. E. Parisi, K. Kantarci, B. F. Boeve, M. K. Pandey, T. Bruinsma, D. S. Knopman, D. T. Jones, L. Petrucelli, C. N. Cook, N. R. Graff-Radford, D. W. Dickson, R. C. Petersen, C. R. Jack, Jr., M. E. Murray, An autoradiographic evaluation of AV-1451 Tau PET in dementia. *Acta Neuropathol Commun* **4**, 58 (2016).

38. M. D. Ikonomovic, E. E. Abrahamson, J. C. Price, C. A. Mathis, W. E. Klunk, [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding. *Ann Neurol* **80**, 307-308 (2016).

39. C. M. Lee, H. I. L. Jacobs, M. Marquie, J. A. Becker, N. V. Andrea, D. S. Jin, A. P. Schultz, M. P. Frosch, T. Gomez-Isla, R. A. Sperling, K. A. Johnson, 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. *J Alzheimers Dis* **62**, 1691-1702 (2018).

40. H. Cho, J. Y. Choi, M. S. Hwang, Y. J. Kim, H. M. Lee, H. S. Lee, J. H. Lee, Y. H. Ryu, M. S. Lee, C. H. Lyoo, In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. *Ann Neurol* **80**, 247-258 (2016).

41. M. Scholl, S. N. Lockhart, D. R. Schonhaut, J. P. O'Neil, M. Janabi, R. Ossenkoppele, S. L. Baker, J. W. Vogel, J. Faria, H. D. Schwimmer, G. D. Rabinovici, W. J. Jagust, PET Imaging of Tau Deposition in the Aging Human Brain. *Neuron* **89**, 971-982 (2016).

42. L. I. Golbe, P. A. Ohman-Strickland, A clinical rating scale for progressive

supranuclear palsy. *Brain* **130**, 1552-1565 (2007).

43. D. R. Williams, J. L. Holton, C. Strand, A. Pittman, R. de Silva, A. J. Lees, T. Revesz, Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. *Brain* **130**, 1566-1576 (2007).

44. A. Arakawa, Y. Saito, T. Seki, A. Mitsutake, T. Sato, J. Katsumata, R. Maekawa, T. Hideyama, K. Tamura, M. Hasegawa, Y. Shiio, Corticobasal degeneration with deep white matter lesion diagnosed by brain biopsy. *Neuropathology*,　(2020).

45. N. Kouri, J. L. Whitwell, K. A. Josephs, R. Rademakers, D. W. Dickson, Corticobasal degeneration: a pathologically distinct 4R tauopathy. *Nat Rev Neurol* **7**, 263-272 (2011).

46. N. J. Cairns, E. H. Bigio, I. R. Mackenzie, M. Neumann, V. M. Lee, K. J. Hatanpaa, C. L. White, 3rd, J. A. Schneider, L. T. Grinberg, G. Halliday, C. Duyckaerts, J. S. Lowe, I. E. Holm, M. Tolnay, K. Okamoto, H. Yokoo, S. Murayama, J. Woulfe, D. G. Munoz, D. W. Dickson, P. G. Ince, J. Q. Trojanowski, D. M. Mann, D. Consortium for Frontotemporal Lobar, Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol* **114**, 5-22 (2007).

47. H. Kroth, F. Oden, J. Molette, H. Schieferstein, F. Capotosti, A. Mueller, M. Berndt, H. Schmitt-Willich, V. Darmency, E. Gabellieri, C. Boudou, T. Juergens, Y. Varisco, E. Vokali, D. T. Hickman, G. Tamagnan, A. Pfeifer, L. Dinkelborg, A. Muhs, A. Stephens, Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. *Eur J Nucl Med Mol Imaging* **46**, 2178-2189 (2019).

48. S. F. Carter, M. Scholl, O. Almkvist, A. Wall, H. Engler, B. Langstrom, A. Nordberg, Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. *J Nucl Med* **53**, 37-46 (2012).

49. H. Shimada, S. Kitamura, H. Shinotoh, H. Endo, F. Niwa, S. Hirano, Y. Kimura, M. R. Zhang, S. Kuwabara, T. Suhara, M. Higuchi, Association between Abeta and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study. *Alzheimers Dement (Amst)* **6**, 11-20 (2017).

50. C. R. Jack, Jr., H. J. Wiste, C. G. Schwarz, V. J. Lowe, M. L. Senjem, P. Vemuri, S. D. Weigand, T. M. Therneau, D. S. Knopman, J. L. Gunter, D. T. Jones, J. Graff-Radford, K. Kantarci, R. O. Roberts, M. M. Mielke, M. M. Machulda, R. C. Petersen, Longitudinal tau PET in ageing and Alzheimer's disease. *Brain* **141**, 1517-1528

(2018).

51. H. Endo, H. Shimada, N. Sahara, M. Ono, S. Koga, S. Kitamura, F. Niwa, S. Hirano, Y. Kimura, M. Ichise, H. Shinotoh, M. R. Zhang, S. Kuwabara, D. W. Dickson, T. Toda, T. Suhara, M. Higuchi, In vivo binding of a tau imaging probe, [(11) C]PBB3, in patients with progressive supranuclear palsy. *Mov Disord*, (2019).

52. D. W. Dickson, Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. *J Neurol* **246 Suppl 2**, II6-15 (1999).

53. M. Goedert, Y. Yamaguchi, S. K. Mishra, M. Higuchi, N. Sahara, Tau Filaments and the Development of Positron Emission Tomography Tracers. *Front Neurol* **9**, 70 (2018).

54. N. A. Murugan, A. Nordberg, H. Agren, Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. *ACS Chem Neurosci* **9**, 1757-1767 (2018).

55. B. Falcon, J. Zivanov, W. Zhang, A. G. Murzin, H. J. Garringer, R. Vidal, R. A. Crowther, K. L. Newell, B. Ghetti, M. Goedert, S. H. W. Scheres, Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. *Nature* **568**, 420-423 (2019).

56. K. Takahata, Y. Kimura, N. Sahara, S. Koga, H. Shimada, M. Ichise, F. Saito, S. Moriguchi, S. Kitamura, M. Kubota, S. Umeda, F. Niwa, J. Mizushima, Y. Morimoto, M. Funayama, H. Tabuchi, K. F. Bieniek, K. Kawamura, M. R. Zhang, D. W. Dickson, M. Mimura, M. Kato, T. Suhara, M. Higuchi, PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. *Brain*, (2019).

57. R. A. Stern, C. H. Adler, K. Chen, M. Navitsky, J. Luo, D. W. Dodick, M. L. Alosco, Y. Tripodis, D. D. Goradia, B. Martin, D. Mastroeni, N. G. Fritts, J. Jarnagin, M. D. Devous, Sr., M. A. Mintun, M. J. Pontecorvo, M. E. Shenton, E. M. Reiman, Tau Positron-Emission Tomography in Former National Football League Players. *N Engl J Med* **380**, 1716-1725 (2019).

58. W. G. Mantyh, S. Spina, A. Lee, L. Iaccarino, D. Soleimani-Meigooni, E. Tsoy, T. J. Mellinger, H. Grant, L. Vandevrede, R. La Joie, O. Lesman-Segev, S. Gaus, K. L. Possin, L. T. Grinberg, B. L. Miller, W. W. Seeley, G. D. Rabinovici, Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy. *JAMA Neurol*, (2020).

59. K. A. Johnson, A. Schultz, R. A. Betensky, J. A. Becker, J. Sepulcre, D. Rentz, E. Mormino, J. Chhatwal, R. Amariglio, K. Papp, G. Marshall, M. Albers, S. Mauro, L. Pepin, J. Alverio, K. Judge, M. Philiossaint, T. Shoup, D. Yokell, B. Dickerson, T.

Gomez-Isla, B. Hyman, N. Vasdev, R. Sperling, Tau positron emission tomographic imaging in aging and early Alzheimer disease. *Ann Neurol* **79**, 110-119 (2016).

60.   A. Shoeibi, N. Olfati, I. Litvan, Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. *Expert Opin Investig Drugs* **27**, 349-361 (2018).

61.   E. E. Congdon, E. M. Sigurdsson, Tau-targeting therapies for Alzheimer disease. *Nat Rev Neurol* **14**, 399-415 (2018).

62.   A. Ishikawa, M. Tokunaga, J. Maeda, T. Minamihisamatsu, M. Shimojo, H. Takuwa, M. Ono, R. Ni, S. Hirano, S. Kuwabara, B. Ji, M. R. Zhang, I. Aoki, T. Suhara, M. Higuchi, N. Sahara, In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. *J Alzheimers Dis* **61**, 1037-1052 (2018).

63.   J. Maeda, M. R. Zhang, T. Okauchi, B. Ji, M. Ono, S. Hattori, K. Kumata, N. Iwata, T. C. Saido, J. Q. Trojanowski, V. M. Lee, M. Staufenbiel, T. Tomiyama, H. Mori, T. Fukumura, T. Suhara, M. Higuchi, In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. *J Neurosci* **31**, 4720-4730 (2011).

64.   Y. Tomita, N. Kubis, Y. Calando, A. Tran Dinh, P. Meric, J. Seylaz, E. Pinard, Long-term in vivo investigation of mouse cerebral microcirculation by fluorescence confocal microscopy in the area of focal ischemia. *J Cereb Blood Flow Metab* **25**, 858-867 (2005).

65.   R. C. Petersen, G. E. Smith, S. C. Waring, R. J. Ivnik, E. G. Tangalos, E. Kokmen, Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* **56**, 303-308 (1999).

66.   G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E. M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-944 (1984).

67.   M. J. Armstrong, I. Litvan, A. E. Lang, T. H. Bak, K. P. Bhatia, B. Borroni, A. L. Boxer, D. W. Dickson, M. Grossman, M. Hallett, K. A. Josephs, A. Kertesz, S. E. Lee, B. L. Miller, S. G. Reich, D. E. Riley, E. Tolosa, A. I. Troster, M. Vidailhet, W. J. Weiner, Criteria for the diagnosis of corticobasal degeneration. *Neurology* **80**, 496-503 (2013).

68.   K. Rascovsky, J. R. Hodges, D. Knopman, M. F. Mendez, J. H. Kramer, J. Neuhaus, J. C. van Swieten, H. Seelaar, E. G. Dopper, C. U. Onyike, A. E. Hillis, K. A. Josephs, B. F. Boeve, A. Kertesz, W. W. Seeley, K. P. Rankin, J. K. Johnson, M. L. Gorno-Tempini, H. Rosen, C. E. Prioleau-Latham, A. Lee, C. M. Kipps, P. Lillo, O. Piguet, J. D. Rohrer, M. N. Rossor, J. D. Warren, N. C. Fox, D. Galasko, D. P. Salmon, S. E.

Black, M. Mesulam, S. Weintraub, B. C. Dickerson, J. Diehl-Schmid, F. Pasquier, V. Deramecourt, F. Lebert, Y. Pijnenburg, T. W. Chow, F. Manes, J. Grafman, S. F. Cappa, M. Freedman, M. Grossman, B. L. Miller, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* **134**, 2456-2477 (2011).

69. M. L. Gorno-Tempini, A. E. Hillis, S. Weintraub, A. Kertesz, M. Mendez, S. F. Cappa, J. M. Ogar, J. D. Rohrer, S. Black, B. F. Boeve, F. Manes, N. F. Dronkers, R. Vandenberghe, K. Rascovsky, K. Patterson, B. L. Miller, D. S. Knopman, J. R. Hodges, M. M. Mesulam, M. Grossman, Classification of primary progressive aphasia and its variants. *Neurology* **76**, 1006-1014 (2011).

70. A. Klein, J. Tourville, 101 labeled brain images and a consistent human cortical labeling protocol. *Front Neurosci* **6**, 171 (2012).

71. J. J. Hauw, S. E. Daniel, D. Dickson, D. S. Horoupian, K. Jellinger, P. L. Lantos, A. McKee, M. Tabaton, I. Litvan, Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology* **44**, 2015-2019 (1994).

72. M. Takei, T. Kida, K. Suzuki, Sensitive measurement of positron emitters eluted from HPLC. *Appl Radiat Isot* **55**, 229-234 (2001).

Acknowledgments: The authors thank all patients and their caregivers for participation in this study, Kazuko Suzuki, Shizuko Kawakami and Momoyo Takanashi for their assistance as clinical coordinators, Yasuharu Yamamoto, Yoshikazu Nakano, Takamasa Maeda and the members of the Translational Team for their support with the PET scans, Hiromi Sano and Naoto Sato for their support with the MRI scans, Jun Maeda, Bin Ji, Takeharu Minamihisamatsu, Shoko Uchida and Kana Osawa for their support with mouse studies, the staff of the Department of Radiopharmaceuticals Development for their radioligand synthesis and metabolite analysis, and Izumi Kaneko, Chieko Kurihara and Atsuo Waki for the monitoring and audit of the study. We thank John Q. Trojanowski and Virginia M-Y. Lee at the Center for Neurodegenerative Disease Research and Institute on Aging, Perelman School of Medicine, University of Pennsylvania, and Akiyoshi Kakita and Hiroshi Shimizu at the Department of Pathology, Brain Research Institute, Niigata University, for kindly sharing postmortem brain tissues, Masato Hasegawa at the Department of Dementia and Higher Brain Function, Metropolitan Institute of Medical

Science for the biochemical analysis, and APRINOIA Therapeutics Inc. for kindly sharing precursor of ^{18}F-PM-PBB3. The authors acknowledge support for the recruitment of patients by Shigeki Hirano and Satoshi Kuwabara at the Department of Neurology, Graduate School of Medicine, Chiba University; Taku Hatano, Yumiko Motoi, Shinji Saiki and Nobutaka Hattori at the Department of Neurology, Juntendo University School of Medicine; Morinobu Seki, Hajime Tabuchi and Masaru Mimura at the Department of Neuropsychiatry, Keio University School of Medicine; Ikuko Aiba at the Department of Neurology, National Hospital Organization Higashinagoya National Hospital; Yasushi Shiio and Tomonari Seki at the Department of Neurology Tokyo Teishin Hospital.

Funding: This study was supported in part by AMED under Grant Number JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049 to M. H., and by MEXT KAKENHI Grant Number JP16H05324 to M. H., JP18K07543 to H. Shimada, JP26117011 to N. S., and by JST CREST Grant Number JPMJCR1652 to M. Higuchi.

Author contributions: K.Tagai and M.Ono conceived the experiments and wrote the paper. Y.Takado, T.S., M.Shigeta, N.S., M.H. and H.Shimada contributed to the conception and design of the study. S.K., K.Takahata, M.K., H.Shinotoh, Y.Sano. and K.M. contributed to the clinical studies through the collection and processing of patient samples, provided clinical data, and provided insight. H.A., H.Suzuki, M.Onaya, T.T., K.A., N.Arai, N.Araki and Y.Saito contributed to the brain biopsy, autopsies and their histological examinations. C.S., Y.K. and M.I. contributed to the kinetic analysis. H.T., M.T. and Y.Tomita contributed to *in vivo* two-photon fluorescence microscopy. K.K., T.K., M Okada and M.-R.Z. contributed to the radioligand synthesis and metabolite analysis. M.Shimojo helped assay validation and writing the manuscript.

Competing interests: H.Shimada., M.-R.Z., T.S., and M.H. hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

Fig. 1. *In vitro* binding of PM-PBB3 to tau lesions in AD, PiD, PSP and CBD.
(**a**) Chemical structural formulae of ^{18}F-PM-PBB3 (left) and ^{11}C-PBB3 (right). (**b**)
Triple staining of tau lesions in the hippocampal formation of an AD patient (left
composite), the frontal cortex of a PiD patient (left composite) and the caudate/putamen
of PSP and CBD patients (right composite) with 25 μM of non-radiolabeled PM-PBB3,
GB, and AT8. NFT, neuropil threads (NT) and dystrophic neurites encompassing a
neuritic plaque (NP) in AD brain sections, pick body (PB) in PiD brain section, and
coiled body (CB), argyrophilic threads (AT), tufted astrocyte (TA) and astrocytic plaque
(AP) in PSP/CBD brain sections are clearly labeled with PM-PBB3. Scale bars, 20 μm.
(**c**) Autoradiographic labeling of AD brain sections including the hippocampal
formation and inferior temporal cortex (left) and a PSP motor cortex section (right) with
5 nM of ^{18}F-PM-PBB3 in the absence (top, total binding) and presence (bottom, non-
specific binding: NSB) of 100 μM of non-radiolabeled PBB5, an analog of PM-PBB3.
(**d**) Photomicrographs of fluorescence staining with PM-PBB3 in areas indicated by
squares in **c**. In line with autoradiographic data, NFT in the AD subiculum (1), and
coiled bodies and tufted astrocytes in middle gray matter layers of the PSP motor cortex
(3) were intensely labeled with 25 μM of non-radiolabeled PM-PBB3, in contrast with
the lack of overt fluorescence signals in the white matter of the AD temporal cortex (2),
and superficial gray matter layers of the PSP motor cortex (4). Scale bars, 20 μm. (**e**)
Total (specific + non-specific) bindings of 1 nM of ^{18}F-PM-PBB3 in AD frontal cortex
(closed circles) and PSP motor cortex (open circles) samples were homologously
blocked by non-radiolabeled PM-PBB3 with varying concentrations, and a one-site
binding model was employed for describing the inhibition plots. Data are mean values ±
SD in four samples and are expressed as % of the averaged total binding. (**f**) Binding
parameters for ^{18}F-PM-PBB3 determined by non-linear fitting of a one-site homologous
blockade model to data shown in **e**. (**g**) Inhibition of total binding of 1 nM of [^{18}F]PM-
PBB3 by clorgiline (MAO-A inhibitor, blue triangle), selegiline (MAO-B inhibitor, red
square) and BTA-1 (analog of PiB, black square) in an AD frontal cortex sample. A part
of ^{18}F-PM-PBB3 total binding was heterologously blocked by BTA-1 with relatively
large Ki (379.1 nM). Total binding of ^{18}F-PM-PBB3 was not inhibited by clorgiline and
selegiline at varying concentrations, while Ki for clorgiline and selegiline was not
determined due to failures of the model fitting. Data are mean values ± SD in four
samples and are expressed as % of the averaged total binding.

Fig. 2. *In vivo* performances of PM-PBB3 as a multimodal probe for optical and PET

imaging of tau aggregates in a transgenic mouse model.

(**a**) Total (specific + non-specific) bindings of 1 nM of ^{18}F-PM-PBB3 in forebrain

samples obtained from rTg4510 transgenic (Tg, closed circles) and non-transgenic (nTg,

open circles) mice were homologously blocked by non-radiolabeled PM-PBB3 with

varying concentrations, and a one-site binding model was employed for describing the

inhibition plots. Data are mean values ± SD in four samples and are expressed as cpm.

(**b**) *Ex vivo* autoradiographic labeling with intravenously injected ^{18}F-PM-PBB3 in 9.7-

month-old Tg (top) and nTg (bottom) control mice. The brains were removed at 30 min

after injection and were cut into sagittal slices. Significant accumulation of ^{18}F-PM-

PBB3 was observed in the hippocampus (arrowhead), neocortex (arrow) and striatum

(circle) of a Tg mouse, but not in the cerebellum (asterisk). On the other hand, no

significant accumulation of ^{18}F-PM-PBB3 showed in these brain areas of a nTg mouse.

(**c**) Postmortem triple staining of Tg brain sections used in *ex vivo* autoradiographic

experiment with 25 µM of non-radiolabeled PM-PBB3, GB and AT8. Numerous

intracellular deposits in the hippocampal (left) and neocortical (right) areas

corresponding to portions indicated by arrowhead and arrow, respectively, in Panel **b**

were strongly labeled with PM-PBB3, GB and AT8. Scale bars, 20 µm. (**d**) *In vivo* two-

photon laser microscopic images showing a maximum intensity projection of

fluorescence signals in a 3D volume of the somatosensory cortex of 8-month-old Tg

(top and middle) and nTg (bottom) mice. Cerebral blood vessels were labeled in red

with intraperitoneally administered sulforhodamine 101, and tau aggregates in the Tg

mouse were illuminated in green with intravenously injected non-radiolabeled PM-

PBB3 (top) or PBB3 (middle), in contrast to minimal retentions of PM-PBB3 in the nTg

mouse brain (bottom). Images were acquired before (Pre) and 5, 30, 90 and 120 min

after the tracer administration. Arrowheads denote the same tau inclusion detected by

PM-PBB3 and PBB3. Scale bars, 20 µm. (**e**) Chronological changes of fluorescence

signals derived from PM-PBB3 (red circles) and PBB3 (blue circles) in identical

neurons bearing tau aggregate in the somatosensory cortex of Tg mouse over 120 min

after the tracer administration in *in vivo* two-photon microscopic imaging. Fluorescence

signal intensities normalized accordingly to the background signals were expressed as

arbitrary units (a. u.), and data are mean values ± SD in 10 neurons. (**f**) Coronal brain

images of 9-month-old Tg (top) and nTg (bottom) mice acquired by averaging dynamic

PET data at 40 – 60 and 10 – 30 min after intravenous administration of ^{18}F-PM-PBB3

(left composite) and ^{11}C-PBB3 (right composite), respectively. Brain volume data were

sectioned at 3 mm (left column in each composite) and 6 mm (right column in each

composite) posterior to the bregma to generate images containing the

neocortex/hippocampus and cerebellum/brainstem, respectively. PET images are

superimposed on individual MRI data, and voxel values represent the SUVR generated

using the cerebellum as reference regions for each radiotracer. (**g, h**) Time-radioactivity

curves (**g**; SUV) and ratio of the radioactivity uptake to the cerebellum (**h**; SUVR) in

the hippocampus of 8-9-month-old Tg (red circles) and nTg (blue circles) mice over 90

and 60 min after intravenous injection of ^{18}F-PM-PBB3 (left) and ^{11}C-PBB3 (right).

Data are mean ± SD in three Tg or nTg animals, and the same individuals were used for

a head-to-head comparison of the two radiotracers.

Fig. 3. AD and PSP tau topologies visualized with high contrast by PET with ^{18}F-PM-PBB3 as compared to ^{11}C-PBB3 in the same human subjects.

(a) Orthogonal ^{18}F-PM-PBB3 and coronal ^{11}C-PBB3 and ^{11}C-PiB-PET images in the same HC, and AD and PSP patients. Images of the PSP patient were derived from an autopsy-confirmed PSP case. Data are displayed as parametric maps for radioligand SUVR. Non-thresholded ^{18}F-PM-PBB3 images are also shown in Supplemental Figure S8. **(b, c)** Time-course changes of the radioligand uptake (**b**; %SUV) and SUVR to the cerebellum (**c**) in the cerebellum (green), temporal cortex (blue) and midbrain (magenta) of representative HC, and AD and PSP patients over 150 min after intravenous injection of ^{18}F-PM-PBB3. **(d-f)** Scatterplots demonstrating head-to-head comparisons of SUVR values between ^{18}F-PM-PBB3 and ^{11}C-PBB3 in the AD (**d**) and PSP (**e**) brains, and between ^{18}F-PM-PBB3 and ^{11}C-PiB in the AD brain (**f**). Significant regression results are also shown. SUVR values were generated from four VOIs in each patient.

Fig. 4. Associations between the clinical disease severity and the extent of areas showing

increased ^{18}F-PM-PBB3 binding in the AD spectrum.

(a) Coronal ^{18}F-PM-PBB3-PET images of HCs and AD patients classified into different

Braak tau stages. **(b)** The topology of increased ^{18}F-PM-PBB3 binding in subjects at each

Braak stage compared to 22 HCs (stage zero). *p* <0.005, uncorrected, for one HC (stage

I/II); *p* <0.05, family-wise error corrected at cluster level, for four MCI/AD patients (stage

III/IV) and for 13 MCI/AD patients (stage V/VI). **(c)** Comparisons of ^{18}F-PM-PBB3

binding in Braak stage VOIs between 23 HCs (white circles) and three MCI (black

squares) and 14 AD (black triangles) cases. *, *p* <0.001 by two-sample t test. **(d)**

Correlation of ^{18}F-PM-PBB3 binding in the Braak stage V/VI VOI with CDRSoB points

in MCI (black squares) and AD (black triangles) patients. *r* = 0.671 and *p* = 0.003 by

Pearson's correlation analysis. Associations between the clinical disease severity and the

extension of ^{18}F-PM-PBB3 binding among MCI/AD patients.

Fig. 5. Associations between clinical disease severity and the extension of ^{18}F-PM-PBB3

binding in PSP-Richardson patients.

(a) Coronal (upper) and axial (lower) ^{18}F-PM-PBB3-PET images of HC and PSP-

Richardson patients with different disease severities scored by PSPRS. The red

arrowheads point to the choroid plexus. PSP patients showed intensification of ^{18}F-PM-

PBB3 binding in the subthalamic nucleus and neighboring thalamic and basal ganglia

areas (yellow arrowhead) and midbrain (green arrowhead) and expansion to the primary

motor and adjacent cerebral cortices containing white matter (white arrowhead) along

with the clinical advancement. The asterisked image was derived from an autopsy-

confirmed PSP case. **(b)** Voxel-based analyses of brain atrophy (voxel-based

morphometry, VBM; red), ^{18}F-PM-PBB3 signal increase (green), and their spatial

overlaps (yellow) in PSP-Richardson patients relative to HCs (p <0.05, family-wise error

corrected at cluster level). Statistical maps are displayed in the Montreal Neurological

Institute coordinate space. **(c)** Comparisons of ^{18}F-PM-PBB3 uptake in subcortical VOIs,

including the globus pallidus (GP), substantia nigra (SN), raphe nucleus (RN), and

subthalamic nucleus (STN) between 23 HCs (white circles) and 16 PSP-Richardson

patients (black circles). *, p <0.001 by two-sample t test. **(d)** Correlation of ^{18}F-PM-PBB3

SUVR values in the STN with PSPRS points. r = 0.566 and p = 0.018 by Pearson's

correlation analysis.

Fig. 6.

PET images of ^{18}F-PM-PBB3 retentions in patients with biopsy-confirmed CBD and

autopsy-confirmed PSP and PiD.

(**a**) Coronal and sagittal brain images of a 68-year-old subject clinically diagnosed as

having CBS (upper panels). Enhanced radioligand binding was observed in the primary

motor and adjacent cortices and subcortical regions, including basal ganglia, subthalamic

nucleus, midbrain, pons and choroid plexus (red arrowheads). Neuropathological assays

of biopsied tissues collected from the middle frontal gyrus revealed the existence of

astrocytic plaques, ballooned neurons and coiled bodies stained with RD4 and/or GB in

the cortex and the corticomedullary junction (lower panels), in agreement with CBD tau

pathologies. (**b**) Axial and coronal ^{18}F-PM-PBB3 PET images of a 65-year-old patient

with a clinical diagnosis of PSP-Richardson (upper panels). The radioligand binding was

augmented in the midbrain, subthalamic nucleus, neighboring subcortical structures and

choroid plexus (red arrowheads). Brain autopsy conducted two years after the PET scan

demonstrated abundant accumulation of tufted astrocytes stained with non-radiolabeled

PM-PBB3, AT8, and GB in the midbrain tegmentum and subthalamic nucleus (lower panels), indicating PSP as a definite diagnosis of this individual. (**c**) Coronal ^{18}F-PM-PBB3 PET images of a 59-year-old patient clinically diagnosed with bvFTD (upper panels). Accumulations of radiosignals were noticeable in the frontal cortex, in contrast with the lack of radioligand binding in the occipital cortex. Brain autopsy was carried out one year after the PET scan, showing great abundance of Pick bodies and neuropil threads stained with non-radiolabeled PM-PBB3 and AT8 in the inferior frontal gyrus (lower panels). This was in sharp distinction from the few tau pathologies in the primary visual cortex (lower panels), collectively supporting a definite diagnosis of this case as PiD. Scale bars, 10 μm (inset), and 100 μm.

Fig. 7. The topology of *in-vivo* ^{18}F-PM-PBB3 binding in patients with diverse clinical

subtypes of FTLD.

Areas with intensified radiosignals, including the primary motor and cortices (white

arrowheads), basal ganglia (yellow arrowheads), subthalamic nucleus/midbrain (green

arrowheads) and choroid plexus (red arrowheads), are indicated in orthogonal ^{18}F-PM-

PBB3 PET images of individual patients. From top to bottom: a 65-year-old male

clinically diagnosed with PSP-Richardson and a PSPRS score of 42 points, and also

autopsy-confirmed PSP; a 62-year-old female clinically diagnosed with PSP-P and a

1   PSPRS score of 20 points; a 65-year-old female clinically diagnosed with non-AD CBS

2   and an MMSE score of 27 points; a 75-year-old male clinically diagnosed with PNFA and

3   an MMSE score of 30 points; and a 72-year-old female clinically diagnosed with bvFTD

4   and an MMSE score of 11 points.

Fig. 8.

A schematic presentation of PET-detectable tau topologies in association with clinical and neuropathological nosologies of FTLD syndromes.

Three tau neuropathologies underlie five clinical phenotypes, and the neocortex-to-subcortex gradient of tau depositions varies as a function of clinicopathological entity and progression of the disease. Patients whose symptomatic manifestations are confined to parkinsonism are likely to exhibit ^{18}F-PM-PBB3 binding localized to subcortical areas (rightward), while patients with cortical symptoms such as apraxia and aphasia may frequently display the radioligand binding primarily in the frontotemporal cortex (leftward).